Skip to main content
. Author manuscript; available in PMC: 2012 Dec 11.
Published in final edited form as: Cancer Chemother Pharmacol. 2011 May 10;68(6):1595–1602. doi: 10.1007/s00280-011-1657-1

Table 3.

Responses

Complete Response 0
Partial Response 7 (13%)
Unconfirmed Complete Response 0
Unconfirmed Partial Response 6 (12%)
Stable Disease 12 (23%)
Progressive Disease 15 (29%)
Symptomatic Deterioration 3 (6%)
Early Death 1 (2%)
Inadequate Assessment 8 (15%)